Market Closed -
Other stock markets
|
After market 03:51:46 pm | |||
3.637 EUR | +1.28% | 3.63 | -0.19% |
Mar. 26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
Mar. 26 | Valneva: Phase 1 trial initiated in the Zika virus | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.94% | 539M | B- | ||
+9.30% | 45.97B | B | ||
+52.73% | 43.93B | A | ||
+7.15% | 42.34B | B- | ||
-8.78% | 28.27B | C | ||
+18.68% | 27.18B | B- | ||
-21.92% | 19.44B | B | ||
+14.62% | 13.83B | C+ | ||
+31.85% | 12.4B | C+ | ||
+4.47% | 11.45B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Valneva - Euronext Paris
- Ratings Valneva